162 related articles for article (PubMed ID: 36743424)
1. Extended disease control with unconventional cabozantinib dose increase in metastatic renal cell carcinoma.
Sharma A; Elias R; Christie A; Williams NS; Pedrosa I; Bjarnason GA; Brugarolas J
Kidney Cancer; 2022; 6(1):69-79. PubMed ID: 36743424
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
[TBL] [Abstract][Full Text] [Related]
3. Cabozantinib use in metastatic renal cell carcinoma patients in clinical practice: Evaluation of dosing patterns, tolerability, and outcomes compared to clinical trials.
McElwee JH; Gourdin TS; Mikoll J; Weeda E; Sion AM
J Oncol Pharm Pract; 2020 Jun; 26(4):861-865. PubMed ID: 31566113
[TBL] [Abstract][Full Text] [Related]
4. Cabozantinib in Patients with Advanced Renal Cell Carcinoma Primary Refractory to First-line Immunocombinations or Tyrosine Kinase Inhibitors.
Santoni M; Massari F; Bracarda S; Grande E; Matrana MR; Rizzo M; De Giorgi U; Basso U; Aurilio G; Incorvaia L; Martignetti A; Molina-Cerrillo J; Mollica V; Rizzo A; Battelli N
Eur Urol Focus; 2022 Nov; 8(6):1696-1702. PubMed ID: 35193819
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.
Rassy E; Cerbone L; Auclin E; Benchimoll-Zouari A; Flippot R; Alves Costa Silva C; Colomba E; Geraud A; Guida A; Mir O; Combarel D; Paci A; Escudier B; Albiges L
Oncologist; 2021 May; 26(5):389-396. PubMed ID: 33554383
[TBL] [Abstract][Full Text] [Related]
6. Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell Carcinoma.
Li H; Sahu KK; Brundage J; Benson M; Swami U; Boucher KM; Gupta S; Hawks J; Sirohi D; Agarwal N; Maughan BL
Oncologist; 2023 Aug; 28(8):737-e693. PubMed ID: 36952231
[TBL] [Abstract][Full Text] [Related]
7. A Phase I/II Clinical Trial of Pembrolizumab and Cabozantinib in Metastatic Renal Cell Carcinoma.
Kessler ER; Callihan E; Hu J; Eule C; Srivastava G; Kemme DJ; Iruku P; Rana V; Moore J; Schuster SR; Amirault M; Flaig TW; Lam ET
Cancer Res Commun; 2023 Jun; 3(6):1004-1012. PubMed ID: 37377613
[TBL] [Abstract][Full Text] [Related]
8. Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population.
Peverelli G; Raimondi A; Ratta R; Verzoni E; Bregni M; Cortesi E; Cartenì G; Fornarini G; Facchini G; Buti S; Galli L; Tucci M; Prisciandaro M; Procopio G
Clin Genitourin Cancer; 2019 Aug; 17(4):291-298. PubMed ID: 31178240
[TBL] [Abstract][Full Text] [Related]
9. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
[TBL] [Abstract][Full Text] [Related]
10. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.
Procopio G; Prisciandaro M; Iacovelli R; Cortesi E; Fornarini G; Facchini G; Cartenì G; Sabbatini R; Del Bene G; Galli L; Caserta C; Multari AG; Bregni M; Massari F; Buti S; De Giorgi U; Zustovich F; Milella M; Calabrò F; Mancini ML; Tortora G; Vernieri C; Santini D; Sorarù M; Ricotta R; Masini C; Tucci M; Fedeli SL; Ortega C; Mecozzi A; Ratta R; Sternberg CN; Verzoni E
Clin Genitourin Cancer; 2018 Aug; 16(4):e945-e951. PubMed ID: 29753637
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Cabozantinib in Metastatic Renal Cell Carcinoma Patients: Towards Drug Expenses Saving Regimens.
Tan Z; Völler S; Yin A; Rieborn A; Gelderblom AJ; van der Hulle T; Knibbe CAJ; Moes DJAR
Clin Pharmacokinet; 2024 Jun; ():. PubMed ID: 38874883
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Toxicity and Clinical Outcomes in Full Versus Reduced Starting Dose Cabozantinib in Metastatic Renal Cell Carcinoma Patients.
Martini DJ; Evans ST; Liu Y; Shabto JM; Uner OE; Olsen TA; Brown JT; Russler GA; Yantorni L; Caulfield S; Goldman JM; Nazha B; Harris WB; Master VA; Kucuk O; Carthon BC; Bilen MA
Clin Genitourin Cancer; 2022 Feb; 20(1):53-59. PubMed ID: 34922840
[TBL] [Abstract][Full Text] [Related]
13. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Loo Gan C; Huang J; Pan E; Xie W; Schmidt AL; Labaki C; Meza L; Bouchard G; Li H; Jackson-Spence F; Sánchez-Ruiz C; Powles T; Kumar SA; Weise N; Hall WA; Rose BS; Beuselinck B; Suarez C; Pal SK; Choueiri TK; Heng DYC; McKay RR
Eur Urol Oncol; 2023 Apr; 6(2):204-211. PubMed ID: 36328934
[TBL] [Abstract][Full Text] [Related]
14. Association of Cabozantinib Dose Reductions for Toxicity With Clinical Effectiveness in Metastatic Renal Cell Carcinoma (mRCC): Results From the Canadian Kidney Cancer Information System (CKCis).
Graham J; Ghosh S; Breau RH; Wood L; Tanguay S; Bosse D; Lalani AK; Bhindi B; Heng D; Finelli A; Fallah-Rad N; Castonguay V; Basappa NS; Soulières D; Pouliot F; Kollmannsberger C; Bjarnason GA
Clin Genitourin Cancer; 2024 Jun; 22(3):102060. PubMed ID: 38521648
[TBL] [Abstract][Full Text] [Related]
15. Cabozantinib in the treatment of metastatic renal cell carcinoma - final data analysis from four oncology centers in the Czech Republic.
Richter I; Poprach A; Zemánková A; Büchler T; Bartoš J; Šámal V; Študentová H; Rozsypalová A; Dvořák J; Brom O; Melichar B
Klin Onkol; 2021; 34(5):392-400. PubMed ID: 34915708
[TBL] [Abstract][Full Text] [Related]
16. Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial.
Choueiri TK; Escudier B; Powles T; Tannir NM; Mainwaring PN; Rini BI; Hammers HJ; Donskov F; Roth BJ; Peltola K; Lee JL; Heng DYC; Schmidinger M; Agarwal N; Sternberg CN; McDermott DF; Aftab DT; Hessel C; Scheffold C; Schwab G; Hutson TE; Pal S; Motzer RJ;
Lancet Oncol; 2016 Jul; 17(7):917-927. PubMed ID: 27279544
[TBL] [Abstract][Full Text] [Related]
17. Real-world Experience of Cabozantinib as Second- or Subsequent Line Treatment in Patients With Metastatic Renal Cell Carcinoma: Data From the Polish Managed Access Program.
Bodnar L; Kopczyńska A; Żołnierek J; Wieczorek-Rutkowska M; Chrom P; Tomczak P
Clin Genitourin Cancer; 2019 Jun; 17(3):e556-e564. PubMed ID: 30987807
[TBL] [Abstract][Full Text] [Related]
18. The correlation between the incidence of adverse events and progression-free survival in patients treated with cabozantinib for metastatic renal cell carcinoma (mRCC).
Kucharz J; Dumnicka P; Kusnierz-Cabala B; Demkow T; Wiechno P
Med Oncol; 2019 Jan; 36(2):19. PubMed ID: 30666498
[TBL] [Abstract][Full Text] [Related]
19. Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Stukalin I; Wells JC; Graham J; Yuasa T; Beuselinck B; Kollmansberger C; Ernst DS; Agarwal N; Le T; Donskov F; Hansen AR; Bjarnason GA; Srinivas S; Wood LA; Alva AS; Kanesvaran R; Fu SYF; Davis ID; Choueiri TK; Heng DYC
Curr Oncol; 2019 Apr; 26(2):e175-e179. PubMed ID: 31043824
[TBL] [Abstract][Full Text] [Related]
20. Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study.
Martínez Chanzá N; Xie W; Asim Bilen M; Dzimitrowicz H; Burkart J; Geynisman DM; Balakrishnan A; Bowman IA; Jain R; Stadler W; Zakharia Y; Narayan V; Beuselinck B; McKay RR; Tripathi A; Pachynski R; Hahn AW; Hsu J; Shah SA; Lam ET; Rose TL; Mega AE; Vogelzang N; Harrison MR; Mortazavi A; Plimack ER; Vaishampayan U; Hammers H; George S; Haas N; Agarwal N; Pal SK; Srinivas S; Carneiro BA; Heng DYC; Bosse D; Choueiri TK; Harshman LC
Lancet Oncol; 2019 Apr; 20(4):581-590. PubMed ID: 30827746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
